• Sobre nosotros
  • Nuestros Productos
  • Pacientes
  • Cirujanos
  • Inversores
  • Contacto
Publicaciones de prensa
Publicaciones de prensaPublicaciones de prensa
Publicaciones de prensa

Home > Sobre nosotros > Publicaciones de prensa

Publicaciones de prensa

Back to previous page

ReGen Biologics Launches Product Distribution in the United Kingdom

April 3, 2008

ReGen Biologics Launches Product Distribution in the United Kingdom

Hackensack, NJ – April 3 ,  2008 – ReGen Biologics (OTC: RGBI) recently signed a distribution agreement and initiated marketing for its products, including the Menaflex™ collagen meniscus implant (formerly CMI®) in the United Kingdom (U.K.).

The U.K. market introduction took place March 18 with two patient surgeries at the Hospital of St. Cross in Rugby, West Midlands.  The surgeries were performed by Mr. Tim Spalding, FRCS Consultant Orthopaedic Surgeon, assisted by Dr. Dirk Holsten of Koblenz, Germany.

ReGen products will be marketed and distributed in the UK through Cardiff-based Hospital Innovations Ltd.  Several training meetings are planned for the Menaflex procedure, and interested surgeons may contact Hospital Innovations directly regarding available dates and locations in the U.K.

“We are pleased to make our Menaflex collagen meniscus implant available to patients and surgeons in the United Kingdom, representing a population of more than 60 million people,” commented Marcel Kyburz, General Manager of ReGen Biologics AG.

U.K. patients are encouraged to log onto www.menaflex.co.uk for more information and a list of trained surgeons.

About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  ReGen’s first approved product using its collagen scaffold technology is the Menaflex™ meniscus application, which is cleared for sale in Europe and other countries and marketed through ReGen’s European subsidiary, ReGen Biologics AG. ReGen continues to work to obtain FDA clearance of the Menaflex device in the United States.

For more information visit www.regenbio.com .
 
Contact:

Marcel Kyburz
ReGen Biologics AG
General Manager
+41 (0) 79 341 28 82
marcel.kyburz@regenbio.com

Brion Umidi    
ReGen Biologics, Inc.    
Chief Financial Officer    
(201) 651-3515    
bumidi@regenbio.com

United Kindgom
Hospital Innovations Ltd.
+44 (0) 292 002 0858
info@hospitalinnovations.com

 
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2006 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at www.regenbio.com, from commercial document-retrieval services and at the Web site maintained by the SEC at www.sec.gov .

NeboWeb Content Management System Tracking